IXICO announces £1.9 million new study award

RNS Announcement

RNS Number : 6936G

IXICO plc

27 November 2020

IXICO plc

("IXICO" or the "Company")

IXICO announces £1.9 million new study award

£1.9 million new business contract for Huntington's disease study with existing biopharmaceutical sponsor

IXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience, today announces that it has executed a contract to provide neuroimaging services that will support a phase Ib/II clinical trial for Huntington's disease.

This will build on the Company's existing relationship with the sponsor with whom they contracted a prior safety and efficacy trial in 2019. By deploying innovative imaging biomarker solutions in early phase studies, IXICO enables biopharmaceutical sponsors to accelerate R&D decision making and maximise the value of their drug development pipelines. The new award reflects and reinforces the confidence customers place in IXICO as the trusted and leading neuroimaging partner for Huntington's disease clinical trials.

This contract was included in management's expectations of performance for the current financial year but adds to the Company's strong order book.

Lammert Albers, Chief Commercial Officer of IXICO, commented: "Huntington's disease is a devastating rare neurological condition with unmet medical needs. IXICO has worked on numerous HD clinical studies since 2007 and is pleased to build further momentum in our mission to support our clients in delivering data analytics in these challenging areas of rare, neurodegenerative disease. Our services will enable clients to measure the impact of the trialled drugs with greater confidence and potentially unlock new insights into disease progression and drug development."

For further information please contact:

IXICO plc			+44 (0)20 3763 7498
Giulio Cerroni, Chief Executive Officer Grant Nash, Chief Financial Officer

Cenkos Securities PLC (Nominated adviser and sole broker)				+44 (0)20 7397 8900
Giles Balleny / Max Gould (Corporate Finance)
Michael F Johnson / Russell Kerr (Sales)

Walbrook PR Ltd	+44 (0)20 7933 8780
Paul McManus / Lianne Cawthorne /		[email protected]
Alice Woodings

About IXICO

IXICO is dedicated to delivering insights in neuroscience. Our purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience and our goal is to be a leading proponent of artificial intelligence in medical image analysis. We will achieve this by developing and deploying breakthrough data analytics, at scale, through our remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for our pharmaceutical clients.

More information is available on www.IXICO.com and follow us on Twitter @IxicOplc

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

CNTFLFIALDLRFII

RNS metadata

Title: IXICO announces £1.9 million new study award
Time: 07:00:01
Date: 27 Nov 2020
Category: Acquisitions and alliances
ID: 6936G